The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...
Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in advanced epithelial ovarian cancer met the primary endpoint of ...
How Was Keytruda Studied for Cervical Cancer? Keytruda was studied in people who had cervical cancer that was newly diagnosed, high risk, locally advanced, and who had not received any prior treatment ...
OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...
Keytruda is not chemotherapy. It’s a type of treatment called immunotherapy. It works with the body’s immune system, helping T cells fight cancer cells. With immunotherapy, the body’s immune system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results